Advanced Colorectal Cancer Clinical Trial
Official title:
High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study
A multicentre phase II study to evaluate the results of high dose simplified folfiri in advanced colorectal cancer
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
| Recruiting |
NCT06200363 -
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT02923622 -
Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer
|
N/A | |
| Completed |
NCT01723969 -
Screening Platform for Clinical Trials in Advanced Colorectal Cancer
|
||
| Active, not recruiting |
NCT00309179 -
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03699111 -
Identification of New Patient Stratification Tools in MSS RAS mt mCRC
|
||
| Not yet recruiting |
NCT02826837 -
LEAC-102 for Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05077839 -
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC
|
Phase 2 | |
| Recruiting |
NCT04324476 -
A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06369259 -
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00707889 -
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT01271166 -
Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT00386828 -
Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial
|
Phase 2 | |
| Recruiting |
NCT04764006 -
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
|
Phase 2 | |
| Active, not recruiting |
NCT04835324 -
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
|
||
| Active, not recruiting |
NCT02619435 -
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT01822444 -
ANGIOPREDICT. ICORG 12-16, V3
|
||
| Completed |
NCT00498407 -
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05731336 -
A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
|
||
| Active, not recruiting |
NCT04744831 -
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
|
Phase 2 |